Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831
Status:
Recruiting
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
The clinical study is designed to evaluate the safety, tolerability and pharmacokinetics of
inhaled nanoparticle nanoparticle formulation of Remdesivir (GS-5734) alone and in
combination with NA-831 in 48 healthy volunteers.